Overview

A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone

Status:
Completed
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
Phase:
Phase 1
Details
Lead Sponsor:
Reata Pharmaceuticals, Inc.
Collaborator:
Covance
Treatments:
Digoxin
Gemfibrozil
Hydroxyitraconazole
Itraconazole
Metformin
Midazolam
Repaglinide
Rosuvastatin Calcium
Verapamil